A new research paper was published in Volume 13 of Oncoscience on February 7, 2026, titled “Reduced immunogenicity of MYC amplified, metastatic prostate cancer.” ...

Discusses First Clinical Outcomes and Precision of TULSA from the CAPTAIN Trial in Prostate Cancer March 13, 2026 11:30 ...

First multicenter, randomized controlled trial directly comparing a new technology to robotic RP for men with localized prostate cancer to ...

The 2026 European Association of Urology (EAU) annual meeting featured a late-breaking abstracts session and a presentation by Dr. Laurence Klotz discussing initial perioperative outcomes of CAPTAIN, ...

News, features, and commentary about cancer-related issues ...

PROSTAID Calgary announces that guest speaker Christine Hentschel of Calgary Meals on Wheels will be featured at its March 18 meeting. The free session will discuss nutrition challenges faced by ...

A meta-analysis explores whether there’s a survival benefit to adding hormone therapy to postoperative radiation for patients with low PSA levels.

Having survived the cancer which took his father, Graham Heron, from Bovington, is urging more men to act quickly to avoid falling victim to the most common cancer affecting men in the UK.

In welcome good news, Telix says the first stage of its pivotal prostate cancer therapeutic trial has hit its desired safety ...

The average age of men who get diagnosed is 67.

Will’s recovery from prostate surgery led to a new level of intimacy with Lucy and brought them closer together ...

MYC amplification is associated with reduced tumor immunogenicity as assessed by the recovery of IR recombination reads from prostate cancer genomics ...